Clinical Trial Update: A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluated the effects of a light breakfast on the safety, tolerability, and pharmacokinetics of odanacatib (MK0822) in osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis

Drugs mentioned

• odanacatib (odanacatib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Osteoporosis | Phase 1 | Status: COMPLETED